PFG Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

PFG Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-466	Closed	-$207K	–	840
2025 Q2	$207K	Buy	+466	New	+$215K	0.01%	602

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PFG Advisors's VRTX Position: Q3 2025 in Review

PFG Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 466 shares — an estimated $207K sold.

PFG Advisors first reported a position in VRTX in Q2 2025 and held it in 1 quarter. The position peaked at $207K in Q2 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

PFG Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
PFG Advisors sold 466 Vertex Pharmaceuticals shares in Q3 2025, an estimated $207K.
PFG Advisors first reported a position in Vertex Pharmaceuticals in Q2 2025 and held it in 1 quarter.
PFG Advisors's Vertex Pharmaceuticals position peaked at $207K in Q2 2025.
1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on PFG Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.